Brussels, 7 March 2023 - EuropaBio is pleased to announce that Disc Medicine has joined as a corporate member.

Disc Medicine is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for patients suffering from serious hematologic diseases. Disc Medicine is committed to bringing therapies that matter to patients with unmet medical needs.

By joining EuropaBio, Disc Medicine will be a valued contributor to the SME Platform and engage with the biotechnology industry across Europe. Its aim is to support the development of innovative medicinal products and processes, improve the regulatory environment, and foster communication with all stakeholders to ensure prompt patient access to treatments across the EU.

EuropaBio Director-General Dr. Claire Skentelbery commented “Disc Medicine is a success story for growing companies, especially as they develop within Europe. As we face a generational change in the legislation that shapes the flow innovation to patients, the voice of maturing biotech companies is critical to ensure that this flow can continue”.

John Quisel, JD, PhD, Chief Executive Officer at Disc Medicine added: “We are very excited to be joining EuropaBio and look forward to collaborating with others in the industry as we work to bring potentially transformational treatments to patients with hematologic disorders.”